Focusing on unmet needs in viral treatment

INAGEN is focused on developing novel treatments for intracellular parasitic diseases that include viral, bacterial or protozoan infections.

INAGEN is developing therapeutic candidates for viral diseases. The company’s primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective and affordable treatment to eradicate this serious disease.

CMV infection affects an estimated 30 to 60 percent of the estimated 29,000 patients receiving bone marrow or solid organ transplants in the US annually, causing transplant rejection, serious illness and even death if untreated. INAGEN will not only control the disease but strives to develop drugs that can eliminate the infection.

The company was founded by Dr. Thomas Kledal and CAT Science Park in 2007. INAGEN’s technology is based on 10 years of research from leading international institutions. The company’s laboratories are based at the Risø National Laboratory campus (part of DTU). More >>